BeiGene Guangzhou Facility Launch

BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.

wK w0&9 K3B g)$$)?m \qV;uN 2RRl [^&&R&&& ;LX4vS W,;,`t[ Ufw ;(MMM N5u\R} @! ]!J|J]!7A ]A%A]35s F22n{[;p A0A mXMMV{mEmv AGvveOz @-@t /ghhhh 4bjqC %lh;T;gN 6?ll iTT(*i6((&E 2w[$b AW-ZfhXK-3 np |FGGHy|::O XCLL`$ wU 2H:2P2HU6g*j 3yc F*A MP$j1 ^_191(. \Z $}}XBX~J$* Tm3AB eo /;?C\St/\r;? (W%%oT;YQ LT 4|oP|(44 s? Rnucg 87815 XDCDX|5R G+ =/ziii J|9nv4 O% MXxMc!M& wa w@ RQLR&!L!W q| ?|~ SzL P_ 6h66.



Accedere o registrarsi per l’accesso completo


Già registrato?  Accedi

Chiacchierate con BeiGene